Secret to stronger pour-over coffee with no extra beans unlocked by scientists
Forget expensive beans and pricey filters – if you want a stronger cup of pour-over coffee, just add water slowly, steadily and from a height, researchers say.
While there are myriad ways to make coffee – from moka pots to cafetieres and barista-style machines – pour-over coffee is an everyday staple for many. Now scientists say they have discovered how to make a stronger cup using the same quantity of ground coffee.
Dr Arnold Mathijssen, a co-author of the study from the University of Pennsylvania, said pouring the hot water slowly from a goose-neck kettle increases the contact time between the water and the coffee grounds, while pouring from a greater height increases mixing, both of which result in more coffee being extracted.
But he added: 'If you pour too slowly, or if you go too high, then the jet tends to break up into these smaller droplets, and that's what you want to avoid as well.'
Writing in the journal Physics of Fluids, Mathijssen and colleagues report how they carried out a number of experiments involving transparent silica gel particles – representing ground coffee – that were illuminated with a laser sheet, which were recorded with a high-speed camera.
While slow pouring increases contact time, the team found that at low heights the velocity of the water was too low to dig into and disturb the bed of particles. Water poured from greater heights resulted in greater agitation of the particles, but the team found that water must flow in an unbroken jet to dig into the bed of particles and displace those at the bottom of the funnel – a process that results in particles building up on the sides and then falling in, creating an avalanche-like effect that increases mixing.
'The increased height compensates for the slow pouring. You only get the avalanche if there is enough energy available,' Mathijssen said.
When the team applied their findings to coffee itself, they found pouring from a greater height resulted in stronger brews, provided an unbroken flow of water was used.
The team add that a good starting point for those at home is to reduce the amount of ground coffee by 10%, say from 20 to 18 grams per cup, then taste the coffee produced by pouring the hot water at different heights – keeping to a limit of about 30cm for safety.
Researchers have previously revealed that to make the perfect espresso every time, it is best to use coffee that is ground slightly coarser than normal.
Both that study and the new research found that the proposed adjustments meant less coffee was needed to produce a drink of given strength. Experts say this is important given that climate breakdown is already causing problems for cultivation of the Coffea arabica plant.
Prof Jamie Foster, of Portsmouth University, who was not involved with the new research but carried out the study on espresso-making, said it seemed 'totally plausible' that the proposed method would lead to a stronger cup of pour-over coffee and a more optimal use of the coffee grounds, and he saw no reason why similar logic could not be applied to cafetiere-style brewing.
'Of course, there is a cheat open to those who prefer cafetiere coffee,' he said. 'That is, put in a spoon and give the grounds a stir, but perhaps a cleverly chosen pour could save dirtying cutlery.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
6 days ago
- The Sun
Cancer treatment turbocharges patients' own blood cells to kill solid tumours for first time
A LIVING cancer drug has been proven to work against solid tumours for the first time. Immune-boosting CAR-T therapy removes a patient's white blood cells and engineers them into highly specialised cancer killers in a lab. 1 They are then injected back into the patient and let loose against the disease. It is currently only used for blood cell cancers like leukaemia but research by Peking University in China has found it can also work against tumours that form as lumps. In a study of 266 people with stomach cancer, patients who received the treatment survived an average of 7.9 months compared to 5.5 months without it. It took 3.3 months for their cancer to worsen, compared to 1.8 months without. Study author Dr Changsong Qi said the results showed a 'significant increase in progression-free survival and clinically meaningful increase in overall survival'. More than 90 per cent of cancers are solid tumours that grow as a physical mass, including the big four of bowel, breast, lung and prostate. The findings raise the hope that tens or even hundreds of thousands more patients will one day benefit from the pioneering approach using their own immune systems instead of harsh drugs. 'Groundbreaking milestone' Dr Carl June, of the University of Pennsylvania, is credited with inventing the therapy and commented: 'This is a groundbreaking milestone for the field of CAR-T therapies against solid tumours.' CAR-T therapy, full name chimeric antigen receptor T-cell therapy, is an advanced type of immunotherapy that turbocharges the body's own defences to fight off cancer. It is intended to be more accurate and cause less collateral damage and side effects by only attacking cancerous cells and not healthy ones. Sun Health Explainer: What is cancer? Young Sunderland fan Bradley Lowery took part in a major clinical trial of it in 2017 before dying from neuroblastoma aged six. It is currently available on the NHS in England for certain types of leukaemia and lymphoma. More than 650 forms of the treatment are now in development for solid cancers. Dr John Haanen, from the Netherlands Cancer Institute, said: 'There is clearly now evidence that this treatment can benefit patients with solid cancers. It is an important development.' The study was published in The Lancet and presented at the conference of the American Society for Clinical Oncology. Dr Catherine Elliott, of Cancer Research UK, said: 'This is an encouraging early sign and further trials will now be needed.'
Reuters
6 days ago
- Reuters
Gilead's CAR-T cell therapy shows promise in deadly brain cancer
CHICAGO, June 1 (Reuters) - A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent glioblastoma, a rare event for a fatal brain cancer with few treatment options, researchers reported on Sunday. The study, presented at the American Society of Clinical Oncology meeting in Chicago and published in Nature Medicine, is the latest among several efforts testing next-generation chimeric antigen receptor T-cell or CAR-T treatments, a type of immunotherapy in which patients' immune cells are engineered to recognize and kill cancer cells. The work, from researchers at the University of Pennsylvania and Gilead's (GILD.O), opens new tab Kite cell therapy unit, tested a dual CAR-T treatment in an effort to overcome the defenses of glioblastoma, the most common brain tumor in adults. CAR-T therapy is already used to treat blood cancers including leukemia, lymphoma and multiple myeloma, and those treatments typically only take aim at one target on the tumor. But solid tumors such as glioblastoma tend to have multiple subpopulations of tumor cells, suggesting that treatments will need more than one target to succeed, said University of Pennsylvania researcher Dr. Stephen Bagley, who led the study. For the treatment, which is injected directly into spinal fluid, the team selected EGFR, which is found in 50% to 60% of all glioblastoma tumors, and a second target called interleukin-13 receptor alpha 2, found in an estimated 75% of glioblastoma tumors. Typically, advanced glioblastoma patients whose cancers return after initial treatment with surgery, radiation and chemotherapy live six to 10 months. Interim results of just six patients were published in March 2024 in Nature Medicine, opens new tab. The current study now includes 18 patients treated with the experimental therapy after their tumors returned following standard treatment. Of these, only 13 had a measurable tumor at the time the cells were introduced, and of those, eight, or 62%, had their tumors shrink, Bagley said. "That was pretty remarkable to us because historically for recurrent glioblastoma tumors, we usually don't see anything shrink them." Several patients lived 12 months or longer, and in one patient, the disease remained stable for 16 months. But so far, the benefit is largely temporary, with many patients relapsing two to three months later. Most patients experienced fevers and neurotoxicity such as lethargy or confusion for two or three days after the cells are injected, but the side effects were manageable, Bagley said. Cindy Perettie, executive vice president of Gilead's Kite cell therapy unit, said she is encouraged by the 62% response. "What we didn't see that we wanted to in a majority of the patients was persistence," she said. Kite is working to develop a third target that will allow the drug to remain in the brain longer. "We will be putting that construct into the clinic sometime next year," she said. Meanwhile, the team wants to test the therapy in 12 patients with newly diagnosed disease. "We know patients in the frontline setting are going to be healthier," she said, and the hope is to see more persistent results. Demand for the trial has been great. Perettie estimates there are 10 times as many patients seeking enrollment for every open slot, and some doctors are referring patients from as far away as Hawaii. "Today, there's only one approved therapy outside of radiation, so for these patients, this is really exciting to see any kind of response," she said. Kite hopes to expand to three or four centers with its triple-target version of the product. "I think we're on the right track," Bagley said, adding that he believes there will be longer-lasting treatments in the next few years.
The Guardian
7 days ago
- The Guardian
Immunotherapy trial helps cancer patients with tumours live 40% longer
Cancer patients treated with a pioneering immunotherapy that genetically modifies their own cells to wipe out tumours live 40% longer, according to 'exciting' and 'groundbreaking' results from a world-first clinical trial. Car T-cell therapy is a new form of immunotherapy where a patient's own T-cells – a type of white blood cell – are tweaked in a lab to target and kill cancer cells. The designer cells are then infused back into their bloodstream to fight the disease. The therapy has already proved successful in treating blood cancers. Now results from the world's first randomised controlled trial of Car T-cell therapy in solid tumours suggest it could be transformative in the fight against these cancers too. Solid tumours represent about 90% of all cancers, including breast, lung and pancreatic cancer. In the trial hailed as a 'milestone' by experts, patients with advanced gastric or gastro-oesophageal junction (GEJ) cancer treated with Car T-cell therapy lived on average approximately 40% longer than patients who received standard care. The results were published in The Lancet and presented at the world's largest cancer conference, the annual meeting of the American Society of Clinical Oncology (Asco), in Chicago. Dr Carl June, a leading expert on Car T-cell therapy at the University of Pennsylvania, who was not involved with the trial, said: 'This is an exciting study showing the first positive results from a randomised trial testing Car T-cells for a solid cancer. 'The study shows that satri-cel Car T-cells provide significant benefits to advanced gastric cancer patients who have failed at least two prior lines of therapy. This represents a groundbreaking milestone for the field of Car-T therapies against solid tumours.' In the trial, more than 100 patients in China with advanced gastric or GEJ cancer were randomised to receive either Car T-cell therapy or one of the standard-of-care medications. Patients who received Car T-cell therapy lived an average of 7.9 months after randomisation, compared with 5.5 months through standard care. Patients receiving the designer immunotherapy also experienced 3.3 months without the cancer advancing compared with 1.8 months in the standard care group. The researchers, from Peking University Cancer Hospital & Institute in Beijing, said Car T-cell therapy 'showed a statistically significant improvement in progression-free survival and clinically meaningful improvement in overall survival'. The results suggest Car T-cell 'could represent a paradigm shift' in care, addressing a crucial unmet need for some patients, they added. Dr Jason Luke, an Asco expert and associate professor of medicine at the University of Pittsburgh, said the results were 'exciting'. He added: 'This is a very important 'plant the flag' publication that should rally the cancer research community to push forward toward improving the lives of patients [with] solid tumours.' A second study on Car T-cell, led by the University of Pennsylvania and due to be presented at Asco on Sunday, suggests the approach can also be used to treat brain tumours. Results from that trial are expected to show Car T-cell can shrink tumours in glioblastoma, an aggressive and fast-growing brain cancer, and help patients live much longer. Car – chimeric antigen receptor – T-cell therapy works by genetically engineering a patient's T-cells to recognise and destroy cancer cells. T-cells are a type of white blood cell that can recognise and destroy foreign cells, including cancer cells, but because cancer is able to evade immune detection, they often miss their mark. Car T-cells are engineered to make them better at detecting cancer cells. Oncologists in Chicago said they were increasingly optimistic that Car T-cell therapy could revolutionise treatment of solid tumours, after dramatic success with blood cancers. 'For solid cancers, there is clearly now not only an interest but evidence that this treatment can benefit patients, making this an important new development that should be shared,' said Dr John Haanen, of the Netherlands Cancer Institute, who will give a presentation on Car T-cell therapy at the Asco meeting. 'I think this [is] a new generation of treatment that wasn't there for medical oncologists before.' Dr Catherine Elliott, the director of research and partnerships at Cancer Research UK, said it was 'encouraging' to see early signs that Car T-cell therapy could help patients with solid tumours. The therapy will need to be trialled in larger numbers of patients before being rolled out widely, Elliott said, but 'could mark an important step forward for patients with limited treatment options'.
